Richard Douglas Net Worth

The estimated Net Worth of Richard Douglas is at least $442 Mille dollars as of 12 June 2024. Richard Douglas owns over 6,670 units of Aldeyra Therapeutics Inc stock worth over $271,865 and over the last 14 years he sold ALDX stock worth over $0. In addition, he makes $169,675 as Independent Chairman of the Board at Aldeyra Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Douglas ALDX stock SEC Form 4 insiders trading

Richard has made over 18 trades of the Aldeyra Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 6,670 units of ALDX stock worth $41,287 on 12 June 2024.

The largest trade he's ever made was buying 200,000 units of Aldeyra Therapeutics Inc stock on 11 May 2017 worth over $186,000. On average, Richard trades about 17,286 units every 119 days since 2011. As of 12 June 2024 he still owns at least 43,920 units of Aldeyra Therapeutics Inc stock.

You can see the complete history of Richard Douglas stock trades at the bottom of the page.

Richard Douglas biography

Dr. Richard H. Douglas Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Douglas has served on our Board of Directors since September 2016. Dr. Douglas is the former Senior Vice President, Corporate Development of Genzyme Corporation. Since 2011, Dr. Douglas has been an independent consultant and advisor at Red Sky Partners LLC. From 1989 to 2011, he led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly-traded clinical-stage vaccine company, and MaxCyte, Inc., a publically traded biotechnology company. Dr. Douglas also serves on the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. Dr. Douglas’ extensive knowledge of our business, experience as a board member of a publicly-traded biotechnology company, substantial scientific background, and expertise in developing, financing and providing strong executive leadership within the pharmaceutical industry contributed to our conclusion that he should serve as a director of our company.

What is the salary of Richard Douglas?

As the Independent Chairman of the Board of Aldeyra Therapeutics Inc, the total compensation of Richard Douglas at Aldeyra Therapeutics Inc is $169,675. There are 5 executives at Aldeyra Therapeutics Inc getting paid more, with Todd Brady having the highest compensation of $4,141,260.

How old is Richard Douglas?

Richard Douglas is 67, he's been the Independent Chairman of the Board of Aldeyra Therapeutics Inc since 2016. There are 2 older and 12 younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.

What's Richard Douglas's mailing address?

Richard's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, MD, 20878.

Insiders trading at Aldeyra Therapeutics Inc

Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson... e Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.

What does Aldeyra Therapeutics Inc do?

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise

Complete history of Richard Douglas stock trades at Aldeyra Therapeutics Inc e Novavax

Aldeyra Therapeutics Inc executives and stock owners

Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Brady,
  President, Chief Executive Officer, Director
• Joshua Reed,
  Chief Financial Officer
• David McMullin,
  Chief Commercial Officer
• Dr. Todd C. Brady M.D., Ph.D.,
  CEO, Pres & Director
• Joshua Reed M.B.A.,
  Chief Financial Officer
• Richard Douglas,
  Independent Chairman of the Board
• Martin Joyce,
  Independent Director
• Jesse Treu,
  Independent Director
• Ben Bronstein,
  Independent Director
• Gary Phillips,
  Independent Director
• Neal Walker,
  Independent Director
• Scott Solomon,
  IR Contact Officer
• Nancy Miller-rich,
  Independent Director
• Stephen Machatha,
  Senior Vice President, Technical Operations
• James Gow,
  Senior Vice President - Clinical Development
• Bruce Greenberg CPA, M.B.A.,
  VP & Controller
• Dr. Stephen G. Machatha Ph.D.,
  Chief Devel. Officer
• Kelly Mizer,
  VP of Commercial Strategy & Operations
• David J Clark,
  Chief Medical Officer
• Advisors Llcedelman Josephp...,
  
• C. Boyd Clarke,
  Director
• Stephen J Tulipano,
  Chief Financial Officer
• Scott Young,
  Chief Operating Officer
• Bruce Greenberg,
  See Remarks
• Advisors Llcperceptive Life...,
  
• Partners Vi, L.P.Blair Jame...,
  
• & Johnson Johnson & Johnson...,
  
• Vi Associates, L.P.Blair Ja...,